Key result
Substituted phenyl analogues of 5-[[4-(4,5-dihydro-2-oxazolyl)phenoxy]alkyl]-3-methylisoxazoles showed enhanced in vitro activity against human rhinovirus, with mean MICs as low as 0.40 microM.
Answers are grounded in this paper and cite their sources.
Substituted phenyl analogues of 5-[[4-(4,5-dihydro-2-oxazolyl)phenoxy]alkyl]-3-methylisoxazoles show potent in vitro inhibitory activity against human rhinovirus serotypes.
A series of substituted phenyl analogues of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles has been synthesized and evaluated in vitro against several human rhinovirus (HRV) serotypes. Substituents in the 2-position greatly enhanced activity when compared to the unsubstituted compound. Many of these compounds exhibited mean MICs (MIC) against five serotypes as low as 0.40 microM. The mean MIC correlated well (r = 0.83) with the MIC80 (the concentration that inhibited 80% of the serotypes tested). A quantitative structure-activity relationship study indicated a strong dependency of MIC on lipophilicity (log P) in combination with inductive effects (sigma m) and bulk factors (MW).
No takes yet. Share an insight, caveat, or question.
Diana et al. (1987) studied Human rhinovirus (HRV). Substituted phenyl analogues of 5-[[4-(4,5-dihydro-2-oxazolyl)phenoxy]alkyl]-3-methylisoxazoles vs. Unsubstituted compound was evaluated on Mean MIC against five HRV serotypes. Substituted phenyl analogues of 5-[[4-(4,5-dihydro-2-oxazolyl)phenoxy]alkyl]-3-methylisoxazoles showed enhanced in vitro activity against human rhinovirus, with mean MICs as low as 0.40 microM.
Synapse has enriched 10 related papers. Consider them for comparative context: